

WHO Prequalification Programme
WHO PUBLIC ASSESSMENT REPORT (WHOPAR)

[CV026 trade name]*

Nirmatrelvir 150 mg tablets + Ritonavir 100 mg tablets Co pack

[CV026 trade name], manufactured at Shanghai Desano Bio-Pharmaceutical Co., Ltd, Shanghai P.R. China, was included in the WHO list of prequalified medicinal products for the treatment of coronavirus disease 2019 (COVID-19) on 27 September 2024.

[CV026 trade name] is currently indicated for treatment of coronavirus disease 2019 (COVID-19) in adults who do not require supplemental oxygen and whose disease is at higher risk for progressing to severe COVID-19. Detailed information on the use of this product is described in the summary of product characteristics (SmPC), which can be found in this WHOPAR.

The active pharmaceutical ingredient(s) of [CV026 trade name] are nirmatrelvir and ritonavir.

The efficacy and safety of nirmatrelvir and ritonavir are well established based on extensive clinical experience in the treatment of coronavirus disease 2019 (COVID-19).

For details on the uses of this product and for side effects and warnings, see Part 4 of this WHOPAR (summary of product characteristics).

On the basis of data submitted and public information on the use of nirmatrelvir and ritonavir, the team of assessors advised that [CV026 trade name] is of acceptable quality, efficacy and safety to allow inclusion of [CV026 trade name] in the list of prequalified medicinal products.

Summary of prequalification status for [CV026 trade name]:

The table shows the status of relevant completed activities, including the dates of WHO internal quality assurance.

* Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility.

The table shows the status of relevant completed activities, including the dates of WHO internal quality assurance.

Initial acceptance	Date	Outcome
Status on PQ list	27 September 2024	listed
Pharmaceutical quality	29 July 2024	MR
Bioequivalence	31 July 2024	MR
Safety, efficacy	NA	NA
GMP (re-)inspection		
APIs	07 July 2023	MR
FPP	20 March 2024	MR
GCP/GLP (re-)inspection	24 May 2024 15 June 2024 19 July 2024	MR
API: active pharmaceutical ingredient FPP: finished pharmaceutical product GCP: good clinical practice [quality standard] GLP: good laboratory practice [quality standard] GMP: good manufacturing practice [quality standard] MR: meets requirements NA: not applicable, not available PQ: prequalification		